🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Procter & Gamble Health Limited PGHL NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.pghealthindia.com
Company Profile ↓
₹6,941.50
+26.84% 1Y
Mkt Cap₹11,522.46 Cr
P/E57.37
P/B21.73
Div. Yield1.32%
52W High₹6,941.50
52W Low₹4,778.60
Book Value₹316.01
EPS (TTM)₹121.00

Company Overview

Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. The company offers over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. Procter & Gamble Health Limited was incorporated in 1967 and is headquartered in Mumbai, India. Procter & Gamble Health Limited is a subsidiary of Procter & Gamble Overseas India B.V.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 62.3%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 76.8%.

Consistent Profit Growth

Net profit has compounded at 19.3% per year over the last five years.

Healthy Margins

Maintains a net profit margin of 23.2%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹1,407.97 Cr (+24.7% YoY); net profit ₹326.91 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +24.7%, earnings +62.7%.
  • 5-Year Trend Long-term compounding — revenue CAGR 8.8%, profit CAGR 19.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:8.84%
1 Year:24.66%

Compounded Profit Growth

5 Years:19.30%
1 Year:62.66%

Stock Price Performance

1 Year:+26.84%
6 Months:+25.31%
3 Months:+40.54%
1 Month:+11.48%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 100% of range
₹4,778.60 ₹6,941.50
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)77.78 · Overbought
Price Performance
1M+11.48%
3M+40.54%
6M+25.31%
1Y+26.84%
Valuation vs Sector

P/E of 57.37 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 62.3%.
  • Healthy ROCE of 76.8%.
  • Excellent profit margin of 23.2%.
  • Profit CAGR of 19.3% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 57.4.
  • RSI at 78 suggests overbought conditions.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
57.37
Industry PE
39.97
Forward P/E
25.94
PEG Ratio
-
Book Value
₹316.01
Price to Book
21.73
P/S
8.10
EV/EBITDA
24.58
Dividend Yield
1.32%

Growth (CAGR)

Revenue 5Y
8.84%
Profit 5Y
19.30%
Revenue (YoY)
24.66%
Earnings (YoY)
62.66%

Profitability & Returns

ROCE
76.81%
ROE
62.32%
ROA
38.86%
Profit Margin
23.22%
Op Margin
30.76%
Gross Margin
74.07%
EPS (Latest Qtr)
₹56.99
EPS (TTM)
₹121.00

Balance Sheet & Liquidity

Debt/Equity
1.77
Quick Ratio
1.65
Current Ratio
2.18
Debt
₹9.29 Cr
Total Assets
₹841.35 Cr
Current Assets
₹556.26 Cr
Working Capital
₹301.33 Cr

Ownership

Promoter Holding
52.20%
Chg in Prom Hold
-
FII / Inst Holding
16.45%
Chg in FII Hold
-0.01%

Financial Snapshot

Enterprise Value
₹11,522.46 Cr
Total Revenue (TTM)
₹1,407.97 Cr
EBITDA
₹474.00 Cr
Free Cash Flow
₹322.28 Cr
Operating Cash Flow
₹337.79 Cr
Shares Outstanding
₹1.66 Cr
Gross Margin
74.07%
Payout Ratio
78.70%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 PGHL Procter & Gamble Health Limited NSEPHARMA 6,941.50 57.37 ₹11,522.46 Cr 1.32% 76.81% 62.32% 8.84% 19.30%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue --310.99 Cr338.74 Cr324.92 Cr373.86 Cr370.45 Cr
Cost of Revenue --98.72 Cr93.99 Cr68.40 Cr109.82 Cr92.87 Cr
Gross Profit --212.27 Cr244.75 Cr256.52 Cr264.04 Cr277.58 Cr
Operating Expenses --136.72 Cr159.85 Cr142.33 Cr159.48 Cr148.16 Cr
Operating Income --75.55 Cr84.90 Cr114.19 Cr104.56 Cr129.42 Cr
EBITDA --84.03 Cr94.37 Cr125.22 Cr114.82 Cr139.59 Cr
Interest Expense --13.00 L12.00 L12.00 L10.00 L21.00 L
Pretax Income --78.53 Cr88.81 Cr119.02 Cr108.82 Cr133.21 Cr
Tax Provision --17.35 Cr22.63 Cr30.48 Cr31.23 Cr38.61 Cr
Net Income --61.18 Cr66.18 Cr88.54 Cr77.59 Cr94.60 Cr
Diluted EPS --36.8639.8753.5446.7456.99

Profit & Loss (Annual)

Figures in INR.

Metric Jun 2021Jun 2022Jun 2023Jun 2024Mar 2026
Revenue -1,092.04 Cr1,205.86 Cr1,129.49 Cr1,407.97 Cr
Cost of Revenue -367.11 Cr392.13 Cr359.49 Cr365.08 Cr
Gross Profit -724.93 Cr813.73 Cr770.00 Cr1,042.89 Cr
Operating Expenses -477.12 Cr517.88 Cr490.89 Cr609.82 Cr
Operating Income -247.81 Cr295.85 Cr279.11 Cr433.07 Cr
EBITDA -280.87 Cr343.07 Cr301.44 Cr474.00 Cr
Interest Expense -42.00 L77.00 L72.00 L55.00 L
Pretax Income -253.37 Cr314.20 Cr273.32 Cr449.86 Cr
Tax Provision -60.85 Cr84.73 Cr72.34 Cr122.95 Cr
Net Income -192.52 Cr229.47 Cr200.98 Cr326.91 Cr
Diluted EPS 107.00116.00138.00121.00-

Balance Sheet (Annual)

Figures in INR.

Metric Jun 2021Jun 2022Jun 2023Jun 2024Mar 2026
Total Assets -888.12 Cr1,101.19 Cr794.36 Cr841.35 Cr
Current Assets -608.04 Cr796.10 Cr524.22 Cr556.26 Cr
Cash & Equivalents -319.40 Cr435.05 Cr238.50 Cr177.24 Cr
Inventory -115.21 Cr134.94 Cr109.11 Cr136.65 Cr
Receivables -83.44 Cr115.71 Cr85.33 Cr164.26 Cr
Total Liabilities -271.63 Cr350.30 Cr256.12 Cr316.80 Cr
Current Liabilities -231.90 Cr303.90 Cr218.91 Cr254.93 Cr
Long Term Debt -----
Total Debt -2.83 Cr12.00 Cr9.56 Cr9.29 Cr
Total Equity -616.49 Cr750.89 Cr538.24 Cr524.55 Cr
Shares Outstanding -1.66 Cr1.66 Cr1.66 Cr1.66 Cr

Cash Flows (Annual)

Figures in INR.

Metric Jun 2021Jun 2022Jun 2023Jun 2024Mar 2026
Operating Cash Flow -169.52 Cr236.00 Cr228.29 Cr337.79 Cr
Investing Cash Flow --25.54 Cr-21.50 Cr-6.87 Cr1.26 Cr
Financing Cash Flow --288.63 Cr-98.47 Cr-418.11 Cr-343.92 Cr
Capital Expenditure --37.92 Cr-42.48 Cr-21.73 Cr-15.51 Cr
Free Cash Flow -131.60 Cr193.52 Cr206.56 Cr322.28 Cr
Net Change in Cash --144.65 Cr116.03 Cr-196.69 Cr-4.87 Cr

Ratios (Annual)

Figures in %.

Metric Jun 2021Jun 2022Jun 2023Jun 2024Mar 2026
Gross Margin % -66.4%67.5%68.2%74.1%
Operating Margin % -22.7%24.5%24.7%30.8%
Net Margin % -17.6%19.0%17.8%23.2%
ROE % -31.2%30.6%37.3%62.3%
ROCE % -37.8%37.1%48.5%73.8%

Shareholding Pattern

Insiders
52.20%
Institutions
16.45%
Public Float
34.42%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PGHL

Google News ue, 13 Jan 2026

Procter & Gamble Health Limited's (NSE:PGHL) stock price dropped 6.6% last week; public companies would not be happy - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxQZlZ3ZXY0S3gwZGxfWHVhbVN1OVpETEthNzhNNWFBVEJBUlZhYTVObFEwdVlQRGF0OGRiaEFjbzVqVjloLW5pM050V1BiaGNqa2lYVW94MXBRUGJkMXRIVTBmd3RqQ2Vrc2plcGJKZ3R0OFBYT0VnYzg4dVNGMndXXzlYajUwblhiZ2luQ0…

Google News Mon, 09 Feb 2026

PGHL shares surges 3% on strong Q3 results, special dividend - BusinessLine

<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxOQ2Rmbno3SzBTemRaMUxQUXlUamhjcFZLQ2hPTDhuM0YyeGpCWjJUQXRrUm5Ud0kzZk5yS25BVWlMY3hRbDlGRzVFZmpLYmNiLV9JcjZzT19leXYxQkN4dmtTdzZObmswWThIdzFQdDM0Vy1sYnRNRXZEbFNoNWJqN0JMVThTSDE4ZzFGMm…

Google News Mon, 25 May 2026

Is Now The Time To Put Procter & Gamble Health (NSE:PGHL) On Your Watchlist? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxOTGpGV0tCbmNpOWhQNWZJZ1dzdzUwZEJJZE5DaTBRU2ZUQzl5Z09IOHhxOXI2ZkZhYnlYakxNRldZb203RklOdGVtV0FWMEFBVlRzT3hobERJS1hWRnVYOXk4ZnI0SlZSM1o3YWxYeENxVDZVOGhON0hoTWZNalR5TVdmVlZCZmRkWk9yZV…

Google News ue, 26 May 2026

Procter & Gamble Health Limited Schedules Board Meeting for May 26, 2026 to Review FY26 Financial Results and Final Dividend - scanx.trade

<a href="https://news.google.com/rss/articles/CBMiigJBVV95cUxPaHdZZUM1dWwtT0FSaS1Ya0hHR2Y4VFZjTDVZSmlFQ3cyc3VVUkFkT3dxQjk1ZjNvaHo2ZEVqX1dqN1VwcVR5NVRoQldKNEh3eFFmUUpsLUVNRWZnQ09JWXZnQkswenV1bHlzbzVzUnFlQkJwaF9TM25GZ09CeERSNUlGMkhHcVBleUEwTk…

Google News ue, 26 May 2026

Procter & Gamble Health shares rally 19% after strong earnings; check all Q4 numbers - Upstox

<a href="https://news.google.com/rss/articles/CBMi9wFBVV95cUxOLUhycEEyb2NLTHhHbVh2djdxalFxTzdBdWNNay10Ylo1LTA5REtwS3EtLWltekFWblRkcUZxNlVhZlVad1Eya1FKRlhhbldTbXFjUnNqbnFrR0twSnNhaVNBb2c5MHpBZjNrWDRPa0Q4OWRfclUwMXlCbWZTQVZXaThkODdmcHNkbE1tdD…

Google News Mon, 18 Aug 2025

PHL recommends shareholders to accept share-swap offer - Trinidad and Tobago Newsday

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxOeVdDb0VqLVA3T3dyTWRwRHFuTHEzTng4U2t0V3o2UFJqQjBkMkI1R1c3YVQ2dU1Wa2E1V2NxSmtsOEwxSjZMNWJYZEQ1N3lCWTh4aTIwa0plTV9Ka0JCUGJBckFEOS1DOHlUYm5xbE85R2RCamhrUFlHVUlRa0hoVU1OY29hcFhURjZpZ2…

PGHL — Frequently Asked Questions

What is the current share price of Procter & Gamble Health Limited (PGHL)?

As of 2026-07-15 09:52 IST, Procter & Gamble Health Limited (PGHL) trades at ₹6,941.50 on NSE. Its 52-week range is ₹4,778.60 to ₹6,941.50.

What is the market capitalisation of PGHL?

Procter & Gamble Health Limited (PGHL) has a market capitalisation of ₹11,522.46 Cr on NSE.

What is the P/E ratio of PGHL?

PGHL trades at a trailing price-to-earnings (P/E) ratio of 57.37. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 21.73.

Does PGHL pay a dividend?

Procter & Gamble Health Limited (PGHL) currently offers a dividend yield of 1.32%.

What is the return on equity (ROE) of PGHL?

PGHL has a return on equity (ROE) of 62.32%. Its return on capital employed (ROCE) is 76.81%.

Is PGHL a good stock to buy?

This page provides a data-driven analysis of Procter & Gamble Health Limited (PGHL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space